Mr. Sun is a seasoned life science executive with more than a decade of experience and a strong track record in biotechnology. In addition to Full-Life, he is Partner and Chief Investment Officer at Gordian Ventures, a global life science venture firm focusing on the incubation of companies that possess extremely high technical barriers for entry. Prior to Gordian, he co-founded Silicon Therapeutics and led the company as CEO through its $2.0 billion acquisition by Roivant Sciences (NASDAQ:ROIV) in February 2021.Previously, he served as CEO or Managing Partner at a wide range of healthcare companies and venture capital firms.

Steffen serves as Chief Medical Officer of Full-Life and is responsible for our targeted radiopharmaceuticals to enter clinical trials. Dr. Heeger began his pharmaceutical career at Merck KGaA where he played a key role over nine years in the development of Erbitux^®, a monoclonal antibody therapeutic targeting EGFR. Following Merck KGaA, he joined Morphosys and served for five years as Vice President and Head of Clinical Development. During that time, he led the clinical development of multiple therapeutic monoclonal antibodies for cancer against targets including PSMA, CD38 and CD19. The anti-CD19 work led to the approval of Monjuvi^® (tafasitamab-cxix) for the treatment of Diffuse Large B-Cell Lymphoma, the first registered drug clinically developed by Morphosys. After Morphosys, Dr. Heeger served in Chief Medical Officer positions at Selvita, S.A. where he advanced the company's lead anti-cancer compound through IND and its initial clinical trial, and NBE Therapeutics, where he oversaw the IND submission and initial clinical trial for its antibody drug conjugate NBE-002 for the treatment of solid tumors and lymphoma. NBE was subsequently acquired by Boehringer Ingelheim for $1.5 billion. Most recently, he held the CMO position at Pega-One, a clinical stage oncology company that went IPO under the umbrella of Centessa Pharmaceuticals. Dr. Heeger holds MD and Master of Healthcare Management (MSc) degrees from the University of Heidelberg (Germany). He trained as a clinical oncologist at the University Hospital Heidelberg, Department of Haematology and Oncology and at German Cancer Research Center.

Fa serves as Full-Life's Chief Scientific Officer and he will further strengthen Full-Life's discovery capabilities, including our radionuclide-drug conjugate (RDC) platforms and therapeutic programs. Dr. Liu, prior to founding Focus-X, served as the Head of Chemistry at Novo Nordisk Research Centers in the US, leading peptide and protein therapeutics discovery. Previously, Dr. Liu was the Head of Chemistry at Calibrium LLC, where he played instrumental roles in building the company's pipeline until its acquisition by Novo Nordisk. Dr. Liu started his industrial career at Eli Lilly, where he led multiple peptide lead optimization efforts and established the well-recognized modern insulin chemistries. Prior to Lilly, Dr. Liu worked at National Cancer Institute focusing on cancer drug discovery. Dr. Liu has discovered five compounds that progressed into human studies, including NNC0480-0389 (Phase II). He also contributed to the discovery of LY3209590 (Phase III) and the FDA approved drug Lyumjev® (insulin lispro-aabc). He received his Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.

Dr. Ting is a scientist, entrepreneur, and angel investor. Before joining Full-Life, he was the first China General Manager of Amersham International Plc. During his tenure at Amersham, he started a very successful joint-venture with China Isotope Corporation, CICAM, one of the world’s largest smoke detector alpha-foil manufacturers and he played a role in the launch of Amersham Kexing Pharmaceutical (Shanghai) a joint venture with C.A.S. Shanghai Inst. of Nuclear Research for the cyclotron production of medical radioisotopes. Additionally, he served as CEO and co-founder of Nanomab Technology, Oxford Vacmedix, and Biovue Technology Ltd., and was a co-founder of Genemedix Plc., a biotechnology company that was co-listed on the main boards of LSE and SSE before its acquisition by the Reliance Group. He has also served in consulting capacities with Westinghouse Electric, Johnson & Johnson, GE Healthcare, CGN Nuclear Technology, and ITM GmbH. Dr. Ting received his D.Phil. from Oxford University and held a permanent university senior research staff position under Professor J.E. Baldwin’s group before pursuing a career in the industry.

Philippe Van Put serves as General Manager, Europe, where he is responsible for the logistics, production, and daily operations of our Belgium site. He has been in the nuclear radioisotope industry for more than 25 years and has served in executive management roles covering raw material supply, logistics, commercial, and business development – most recently at IRE, one of the largest radioisotope production companies worldwide. His extensive experience in the radiopharmaceutical area allows him to develop strong relationships with many experts within the industry. He received his master’s degree in applied sciences (radiation safety and applications of ionizing radiation) from the Catholic University of Louvain-la-Neuve, Belgium.

Dr. de Jong, joins Full-Life with 43 years leadership experience and expertise in accelerator physics, and isotope production, including commercial-scale radioisotope production using linear accelerators. He joined Full-Life from Canadian Isotope Innovations Corp., where he served as Chief Technology Officer. At Canadian Isotope Innovations Corp., he spearheaded the development and operation of the MIP (Medical Isotope Production) facility with a 35 MeV electron linear accelerator dedicated to medical isotope production. His responsibilities included leading the development of new radioisotopes for medical applications utilizing electron accelerators, as well as leading the development of electron accelerators and target technology for medical isotope production. Previously, Dr. de Jong held the position of Chief Medical Isotope Officer at Canadian Light Source Inc. (CLS). During his tenure there, he led the development, operation, and commercialization of the MIP facility using a 35 MeV electron linear accelerator dedicated to producing Molybdenum-99 (99Mo) for medical applications. His leadership has been instrumental in numerous successful groundbreaking projects, including the design and commissioning of a 2.9 GeV electron synchrotron for CLS, and pioneering a photo-neutron method for producing 99Mo. He has also developed critical software tools for nuclear safety systems for power plants, ensuring their safe operation.  Dr. de Jong's distinguished career is marked by his exemplary leadership and active participation in numerous prestigious national and international committees. Notably, he served as the Chief Scientific Investigator for the International Atomic Energy Agency's Coordinated Research Project on new methods for producing Technetium-99m (Tc-99m), a critical medical isotope. He has also held leadership positions on international advisory committees, including the Taiwan Photon Source and the Shanghai Synchrotron Radiation Facility. Dr. de Jong's dedication to scientific advancement is further evidenced by his contributions to international organizations like the International Electrotechnical Commission and the OECD Nuclear Energy Agency. Dr. de Jong's contributions to the field have been recognized with renowned awards, including the AECL Distinguished Merit Award and the University of Manitoba Honoured Alumni Award. He holds a PhD in Physics from the University of Manitoba.

Julie is a seasoned pharmaceutical strategy and business development executive with a wealth of experience in the U.S. and China in investment banking, business development, and strategic planning, as well as business operations. Prior to Full-Life, she worked with numerous pharmaceutical companies, including Eli Lilly, Abbott, and Novartis, as well as with Citibank. Julie received her MBA degree in Finance from the Wharton School of the University of Pennsylvania.